Cargando…

Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease

Diabetic kidney disease (DKD), as the main complication of diabetes mellitus, is the primary cause of the end-stage renal disease (ESRD) and the most common chronic kidney disease. Overall, 30–40% of patients with type 1 and type 2 diabetes eventually develop DKD. Although some diabetes patients hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Heng-Cheng, Dai, Wen-Ni, He, Li-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837569/
https://www.ncbi.nlm.nih.gov/pubmed/33519221
http://dx.doi.org/10.2147/DMSO.S288500
_version_ 1783642981867192320
author Lu, Heng-Cheng
Dai, Wen-Ni
He, Li-Yu
author_facet Lu, Heng-Cheng
Dai, Wen-Ni
He, Li-Yu
author_sort Lu, Heng-Cheng
collection PubMed
description Diabetic kidney disease (DKD), as the main complication of diabetes mellitus, is the primary cause of the end-stage renal disease (ESRD) and the most common chronic kidney disease. Overall, 30–40% of patients with type 1 and type 2 diabetes eventually develop DKD. Although some diabetes patients have intensified glycemic control, they still develop diabetic kidney disease. Current treatment methods can alleviate but do not markedly halt disease development, resulting in renal failure and severe complications, even contributing to elevated morbidity and mortality rates. DKD is a disease with interactions of genes and the environment. Emerging evidence indicates that DKD-associated key genes are also regulated by the epigenetic mechanism. Recently, increasing researches involving cells and experimental animals demonstrated that histone post-translational modifications can mediate gene expression, which correlated with diabetic kidney disease. Novel therapeutic strategies for epigenetic events could be beneficial for the early detection and treatment of DKD to prevent it from developing into end-stage renal disease (ESRD). In this review, we discuss prior findings in the field of histone modifications in DKD, especially histone acetylation and histone methylation. We then focus on recent developments in histone acetylation and methylation involved in the pathogenesis of DKD.
format Online
Article
Text
id pubmed-7837569
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78375692021-01-28 Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease Lu, Heng-Cheng Dai, Wen-Ni He, Li-Yu Diabetes Metab Syndr Obes Review Diabetic kidney disease (DKD), as the main complication of diabetes mellitus, is the primary cause of the end-stage renal disease (ESRD) and the most common chronic kidney disease. Overall, 30–40% of patients with type 1 and type 2 diabetes eventually develop DKD. Although some diabetes patients have intensified glycemic control, they still develop diabetic kidney disease. Current treatment methods can alleviate but do not markedly halt disease development, resulting in renal failure and severe complications, even contributing to elevated morbidity and mortality rates. DKD is a disease with interactions of genes and the environment. Emerging evidence indicates that DKD-associated key genes are also regulated by the epigenetic mechanism. Recently, increasing researches involving cells and experimental animals demonstrated that histone post-translational modifications can mediate gene expression, which correlated with diabetic kidney disease. Novel therapeutic strategies for epigenetic events could be beneficial for the early detection and treatment of DKD to prevent it from developing into end-stage renal disease (ESRD). In this review, we discuss prior findings in the field of histone modifications in DKD, especially histone acetylation and histone methylation. We then focus on recent developments in histone acetylation and methylation involved in the pathogenesis of DKD. Dove 2021-01-22 /pmc/articles/PMC7837569/ /pubmed/33519221 http://dx.doi.org/10.2147/DMSO.S288500 Text en © 2021 Lu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Lu, Heng-Cheng
Dai, Wen-Ni
He, Li-Yu
Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease
title Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease
title_full Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease
title_fullStr Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease
title_full_unstemmed Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease
title_short Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease
title_sort epigenetic histone modifications in the pathogenesis of diabetic kidney disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837569/
https://www.ncbi.nlm.nih.gov/pubmed/33519221
http://dx.doi.org/10.2147/DMSO.S288500
work_keys_str_mv AT luhengcheng epigenetichistonemodificationsinthepathogenesisofdiabetickidneydisease
AT daiwenni epigenetichistonemodificationsinthepathogenesisofdiabetickidneydisease
AT heliyu epigenetichistonemodificationsinthepathogenesisofdiabetickidneydisease